GO:0032715 negative regulation of interleukin-6 production: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032715 describes any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-6 (IL-6) production.
• IL-6 is a pleiotropic cytokine, and its production is tightly controlled at transcriptional, post-transcriptional, and translational levels.
• Key negative regulators include RNA-binding proteins such as MKRN2, which disrupts Il6 translation, and transcription factors like ARID5B.
• Dysregulation of IL-6 production is implicated in autoimmune diseases, chronic inflammation, and cancer [3,4].
• Experimental models for studying this process include knockout mice, point-mutant cell lines, and reporter assays [1,4].
• CRISPR-based editing enables precise dissection of regulatory elements and candidate genes controlling IL-6 production [1,4].
Description
Interleukin-6 (IL-6) is a multifunctional cytokine that plays central roles in immune response, hematopoiesis, and metabolism. Its production must be tightly regulated to prevent excessive inflammation and tissue damage. The Gene Ontology term GO:0032715, negative regulation of interleukin-6 production, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of IL-6 production. This regulation occurs at multiple levels, including transcription, mRNA stability, and translation. Understanding these mechanisms is critical for developing therapies for inflammatory diseases and cancer. Recent studies have identified diverse negative regulators, such as the RNA-binding E3 ligase MKRN2, which selectively disrupts Il6 translation to restrain inflammation, and ARID5B, a negative modulator of IL-6 production in rheumatoid arthritis synovial fibroblasts. These findings highlight the complexity and therapeutic potential of targeting IL-6 production.
negative regulation of interleukin-6 production At A Glance
| GO ID | GO:0032715 |
|---|---|
| GO term | negative regulation of interleukin-6 production |
| Ontology | biological_process |
| Synonym | inhibition of interleukin-6 production; negative regulation of IL-6 production; downregulation of interleukin-6 production |
| Major function | Suppression of IL-6 cytokine production at transcriptional, post-transcriptional, or translational levels |
| Related processes | Inflammatory response, immune regulation, cytokine signaling |
| Key regulators | MKRN2, ARID5B, GILZ, and others |
| Disease relevance | Autoimmune diseases, chronic inflammation, cancer |
What Is GO:0032715?
GO:0032715, negative regulation of interleukin-6 production, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-6 production. This includes regulation at the levels of gene transcription, mRNA processing, translation, and secretion. It is a biological process ontology term that captures the inhibitory control of IL-6 biosynthesis and release.
Why Is negative regulation of interleukin-6 production Important in Cell Biology?
Negative regulation of IL-6 production is essential for maintaining immune homeostasis and preventing chronic inflammatory diseases. Excessive IL-6 production is associated with rheumatoid arthritis, inflammatory bowel disease, and cytokine storms [3,4]. Understanding the molecular mechanisms that restrain IL-6 production can reveal new therapeutic targets and biomarkers. Moreover, IL-6 plays a role in metabolic regulation, as it negatively regulates hepatic glucose production. Thus, studying GO:0032715 has broad implications for immunology, metabolism, and oncology.
• Prevents excessive inflammation and tissue damage by limiting IL-6 levels.
• Dysregulation leads to autoimmune diseases such as rheumatoid arthritis and psoriasis [3,4].
• IL-6 is a negative regulator of hepatic glucose production, linking inflammation to metabolism.
• Negative regulators like MKRN2 are potential therapeutic targets for inflammatory diseases.
• ARID5B acts as a negative modulator in rheumatoid arthritis synovial fibroblasts.
• GILZ restrains IL-17-mediated skin inflammation, indirectly affecting IL-6 production.
• Cholecystokinin downregulates psoriatic inflammation, possibly via IL-6 regulation.
• Negative energy balance in cows affects IL-6 regulation, highlighting metabolic crosstalk.
• IL-6 trans-signaling promotes progesterone production, indicating reproductive roles.
• OX40/OX40L interaction negatively regulates IL-17 production, which may influence IL-6.
What Happens During negative regulation of interleukin-6 production?
Transcriptional repression of IL6 gene
In simple terms: The cell reduces the reading of the IL6 gene into messenger RNA.
Transcriptional repression involves the binding of repressor proteins to the IL6 promoter or enhancer regions, preventing RNA polymerase II recruitment. For example, ARID5B acts as a negative modulator of IL-6 production in rheumatoid arthritis synovial fibroblasts, likely by competing with transcriptional activators. This step reduces the pool of IL6 mRNA available for translation.
Post-transcriptional regulation of IL6 mRNA
In simple terms: The cell controls how long the IL6 messenger RNA survives or how efficiently it is translated.
RNA-binding proteins can bind to AU-rich elements in the 3' untranslated region of IL6 mRNA, promoting its degradation or inhibiting translation. MKRN2, an RNA-binding E3 ligase, selectively disrupts Il6 translation to restrain inflammation. This ensures rapid dampening of IL-6 production without affecting other cytokines.
Translational inhibition
In simple terms: The cell blocks the production of IL-6 protein from its mRNA.
Translational inhibition can occur through the action of microRNAs or RNA-binding proteins that interfere with ribosome assembly or elongation. MKRN2 directly inhibits Il6 translation, as shown in macrophages. This mechanism provides a fast way to reduce IL-6 levels post-transcriptionally.
Secretion blockade
In simple terms: The cell prevents the release of IL-6 protein outside the cell.
Although less characterized, negative regulation of IL-6 secretion may involve retention of IL-6 in the endoplasmic reticulum or Golgi, or enhanced degradation. The GO term includes negative regulation of interleukin-6 secretion as a synonym, indicating that secretion can be a target of regulation.
Feedback inhibition by signaling molecules
In simple terms: Other signals turn down IL-6 production to keep inflammation in check.
Glucocorticoid-induced leucine zipper (GILZ) regulates Th17 responses and restrains IL-17-mediated skin inflammation, which can indirectly reduce IL-6 production. Similarly, cholecystokinin downregulates psoriatic inflammation, possibly by self-regulatory effects on keratinocytes. These feedback loops are critical for resolving inflammation.
Key Genes Involved in GO:0032715 negative regulation of interleukin-6 production
The following genes and proteins have been experimentally implicated in the negative regulation of interleukin-6 production.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MKRN2 | RNA-binding E3 ligase that disrupts Il6 translation | Restrains inflammation; potential target for inflammatory diseases |
| ARID5B | Negative modulator of IL-6 production in rheumatoid arthritis synovial fibroblasts | Implicated in autoimmune disease pathogenesis |
| GILZ | Regulates Th17 responses and restrains IL-17-mediated skin inflammation | Indirectly affects IL-6 production; anti-inflammatory |
| CCK | Cholecystokinin downregulates psoriatic inflammation | Possible self-regulatory effect on keratinocytes |
| IL6 | The cytokine itself; negative regulation targets its production | Central to inflammatory and metabolic diseases |
| OX40 | OX40/OX40L interaction negatively regulates IL-17 production | May influence IL-6 indirectly |
| OX40L | Ligand for OX40; involved in negative regulation of IL-17 | Potential modulator of IL-6 |
| IL17 | Negatively regulated by OX40/OX40L; can induce IL-6 | Feedback regulation |
| IL6R | IL-6 receptor; trans-signaling promotes progesterone production | Reproductive biology |
| IL6ST | gp130; signal-transducing subunit for IL-6 family cytokines | Downstream of IL-6 signaling |
| STAT3 | Transcription factor activated by IL-6; can feedback regulate IL-6 | Inflammation and cancer |
| NFKB1 | Transcription factor that induces IL-6; negative regulators may inhibit it | Inflammatory signaling |
| CEBPB | Transcription factor that activates IL6; negative regulators may interfere | Inflammation |
| JUN | AP-1 component; involved in IL6 transcription | Inflammation |
| FOS | AP-1 component; involved in IL6 transcription | Inflammation |
| MAPK14 | p38 MAPK; regulates IL-6 production post-transcriptionally | Inflammation |
| ELAVL1 | HuR; stabilizes IL6 mRNA; negative regulators may oppose | mRNA stability |
| ZFP36 | Tristetraprolin; destabilizes IL6 mRNA | Post-transcriptional repression |
How Is negative regulation of interleukin-6 production Regulated?
The negative regulation of IL-6 production is itself controlled by various signaling pathways. For instance, the RNA-binding E3 ligase MKRN2 is induced upon inflammatory stimuli and acts as a feedback inhibitor of Il6 translation. GILZ, a glucocorticoid-induced protein, restrains Th17 responses and IL-17-mediated inflammation, indirectly limiting IL-6 production. Additionally, cholecystokinin downregulates psoriatic inflammation, possibly through self-regulatory effects on keratinocytes. Metabolic status also influences IL-6 regulation, as seen in negative energy balance in cows. These regulatory layers ensure that IL-6 production is finely tuned to the physiological context.
negative regulation of interleukin-6 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ARID5B | Rheumatoid arthritis | Knockout of ARID5B in synovial fibroblasts; IL-6 ELISA |
| MKRN2 | Inflammatory diseases | MKRN2 knockout mice; LPS-induced inflammation |
| GILZ | Skin inflammation | GILZ transgenic mice; imiquimod-induced psoriasis |
| CCK | Psoriasis | CCK knockout mice; keratinocyte-specific deletion |
| IL6 | Metabolic disorders | IL6 knockout rats; hepatic glucose production assay |
Rheumatoid Arthritis
In rheumatoid arthritis, synovial fibroblasts produce excessive IL-6, contributing to joint destruction. ARID5B has been identified as a negative modulator of IL-6 production in these cells, and its dysfunction may exacerbate disease. Targeting negative regulators like ARID5B could restore IL-6 homeostasis.
Psoriasis
Psoriasis is a chronic skin inflammation driven by IL-17 and IL-6. Cholecystokinin downregulates psoriatic inflammation, possibly by self-regulatory effects on epidermal keratinocytes, which may involve negative regulation of IL-6 production. GILZ also restrains IL-17-mediated skin inflammation, indirectly reducing IL-6.
Inflammatory Bowel Disease
Although not directly cited in the provided references, excessive IL-6 production is a hallmark of inflammatory bowel disease. The mechanisms of negative regulation described for GO:0032715 are likely relevant, as MKRN2 restrains inflammation in macrophages.
Metabolic Disorders
IL-6 negatively regulates hepatic glucose production, and its production is altered in metabolic stress such as negative energy balance in cows [2,6]. Dysregulation of negative regulation of IL-6 production may contribute to insulin resistance and type 2 diabetes.
From negative regulation of interleukin-6 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IL-6 production? | CRISPR knockout of gene X in macrophages, measure IL-6 by ELISA |
| Does a point mutation in gene X affect its function? | CRISPR point mutation knock-in in cell lines, IL-6 reporter assay |
| Does gene X interact with IL6 mRNA? | CRISPR knock-in of epitope tag in gene X, RNA immunoprecipitation |
| Does overexpression of gene X reduce IL-6? | Lentiviral overexpression of gene X in fibroblasts, IL-6 quantification |
| Is the regulation dependent on a specific domain? | CRISPR knock-in of domain deletions, IL-6 production assay |
| Can we screen for novel negative regulators? | CRISPR library screening with IL-6 reporter |
How to Study the negative regulation of interleukin-6 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | IL-6 protein levels in supernatants | Quantify production after genetic perturbation |
| qRT-PCR | IL6 mRNA levels | Assess transcriptional regulation |
| RNA-seq | Global transcriptome changes | Identify pathways co-regulated with IL6 |
| Ribo-seq | Translation efficiency | Detect translational inhibition |
| RIP-seq | RNA-protein interactions | Map MKRN2 binding to Il6 mRNA |
| CRISPR screen | Genes affecting IL-6 production | Discover novel negative regulators |
| Western blot | Protein expression and phosphorylation | Validate signaling changes |
| Immunofluorescence | Cellular localization of IL-6 or regulators | Visualize secretion blockade |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify genes whose loss increases IL-6 production, revealing negative regulators. This approach has been used to discover MKRN2 as a selective disruptor of Il6 translation.
RNA Sequencing (RNA-seq)
RNA-seq measures IL6 mRNA levels and can distinguish transcriptional from post-transcriptional regulation. For example, ARID5B knockdown may increase IL6 mRNA in synovial fibroblasts.
Ribo-seq and Polysome Profiling
These techniques assess translation efficiency. MKRN2 was shown to disrupt Il6 translation using polysome profiling.
Proteomics and Immunoprecipitation
Mass spectrometry-based proteomics can identify proteins interacting with IL6 mRNA or regulatory complexes. RNA immunoprecipitation followed by sequencing (RIP-seq) can map binding sites.
How CRISPR Can Be Used to Study GO:0032715 negative regulation of interleukin-6 production
Knockout
CRISPR knockout of candidate negative regulators (e.g., MKRN2, ARID5B) in cell lines or primary cells can confirm their role in suppressing IL-6 production. For instance, MKRN2 knockout macrophages exhibit increased Il6 translation and inflammation.
Point Mutation
Introducing point mutations in regulatory domains (e.g., the RING domain of MKRN2) can dissect structure-function relationships. This helps determine whether E3 ligase activity is required for IL-6 repression.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into endogenous loci allows for precise tracking of protein expression and interaction. Tagged MKRN2 knock-in mice can be used for in vivo studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can test whether increasing a candidate regulator reduces IL-6 production. Overexpression of ARID5B in rheumatoid arthritis synovial fibroblasts may suppress IL-6.
How EDITGENE Supports negative regulation of interleukin-6 production Research
Researchers studying negative regulation of interleukin-6 production-related genes often need to determine whether a candidate gene is causally involved in suppressing IL-6 production or is merely correlated. EDITGENE provides comprehensive CRISPR-based services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-6 production research.
Frequently Asked Questions About negative regulation of interleukin-6 production
What is GO:0032715?
GO:0032715 is the Gene Ontology term for negative regulation of interleukin-6 production, describing any process that reduces the frequency, rate, or extent of IL-6 production.
What genes are involved in negative regulation of interleukin-6 production?
Key genes include MKRN2, ARID5B, GILZ, and CCK, among others [1,3,4,5].
How is IL-6 production negatively regulated?
It can be regulated at transcriptional, post-transcriptional, translational, and secretion levels, often by RNA-binding proteins or transcription factors [1,4].
What diseases are associated with dysregulation of IL-6 production?
Rheumatoid arthritis, psoriasis, inflammatory bowel disease, and metabolic disorders [3,4,5].
What experimental models are used to study negative regulation of IL-6 production?
CRISPR knockout mice, point-mutant cell lines, reporter assays, and RNA immunoprecipitation [1,4].
How does MKRN2 regulate IL-6 production?
MKRN2 is an RNA-binding E3 ligase that selectively disrupts Il6 translation to restrain inflammation.
What is the role of ARID5B in IL-6 regulation?
ARID5B acts as a negative modulator of IL-6 production in rheumatoid arthritis synovial fibroblasts.
Can CRISPR be used to study negative regulation of IL-6 production?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect regulatory mechanisms [1,4].
What is the clinical relevance of negative regulation of IL-6 production?
It is critical for preventing chronic inflammation and autoimmune diseases, and targeting these pathways may yield new therapies [3,4].
How does IL-6 negatively regulate hepatic glucose production?
IL-6 has been shown to negatively regulate hepatic glucose production in isolated rat liver, linking inflammation to metabolism.
Conclusion
Negative regulation of interleukin-6 production (GO:0032715) is a vital biological process that safeguards against excessive inflammation and maintains metabolic homeostasis. Research has uncovered diverse molecular players, including MKRN2, ARID5B, and GILZ, that operate at different levels to restrain IL-6. Understanding these mechanisms offers promising avenues for therapeutic intervention in autoimmune diseases, chronic inflammation, and cancer. Continued exploration using CRISPR-based tools will further illuminate this critical regulatory network.
References
- 1. Yu Z et al.. 2025. The RNA-binding E3 ligase MKRN2 selectively disrupts Il6 translation to restrain inflammation.. Nat Immunol 26(7):1036-1047 PMID: 40524017
- 2. Dent JR et al.. 2016. Interleukin-6 is a negative regulator of hepatic glucose production in the isolated rat liver.. Arch Physiol Biochem 122(2):103-9 PMID: 26808480
- 3. Jones SA et al.. 2015. GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation.. J Autoimmun 61:73-80 PMID: 26077873
- 4. Tagawa Y et al.. 2024. ARID5B is a negative modulator of IL-6 production in rheumatoid arthritis synovial fibroblasts.. Immunol Med 47(3):176-185 PMID: 38747454
- 5. Funakoshi A et al.. 2019. Cholecystokinin Downregulates Psoriatic Inflammation by Its Possible Self-Regulatory Effect on Epidermal Keratinocytes.. J Immunol 202(9):2609-2615 PMID: 30902899
- 6. Wnorowska K et al.. 2025. Molecular Response of Simmental Cows to Negative Energy Balance: Regulation of Interleukin-6 and Plasminogen During Early Lactation.. Int J Mol Sci 26(23) PMID: 41373870
- 7. Li SJ et al.. 2022. The interleukin-6 trans-signaling promotes progesterone production in human granulosa-lutein cells†.. Biol Reprod 106(5):953-967 PMID: 35098302
- 8. Li J et al.. 2008. Negative regulation of IL-17 production by OX40/OX40L interaction.. Cell Immunol 253(1-2):31-7 PMID: 18501882
